Therapeutic Drugs for 40 Renal Transplant Recipients with COVID-19
Objective To provide a reference for the treatment of renal transplant recipients with COVID-19.Methods A retrospective analysis was conducted on the medication data of 40 patients who had met the discharge criteria in the kidney transplantation ward of a grade Ⅲ hospital in Anhui Province from December 6,2022 to January 5,2023.The drug consumption sum and dosage were recorded,and the defined daily dose system(DDDs)and drug utilization index(DUI)were calculated to analyze their medication characteristics.Results The total cost of medication for 40 patients was CNY 2.442 9 million,accounting for approximately 63.71%of the total hospitalization expenses.Among them,the cost of antibiotics was CNY 1.420 9 million,accounting for approximately 58.16%of the total drug cost.The top 10 drugs in terms of DDDs were glucocorticoids,proton pump inhibitors,and antibiotics,and 100.00%of patients used two or more antibiotics in combination,with a maximum of six antibiotics used in combination.A total of 39 patients(97.50%)took Paxlovid or Azovudine,of which 16 patients(40.00%)took the two drugs in combination.A total of 22 patients(55.00%)had adverse drug reactions,mainly characterized by diarrhea(42.50%),dizziness(37.50%),and elevated transaminases(32.50%).Conclusion Renal transplant recipients infected with SARS-CoV-2 during hospitalization is complex and the combination of anti-infective drugs is more frequent.It is necessary to strengthen the pathogenic examination and culture,and carry out anti-infection treatment according to the pathogenic detection results.Pay attention to the occurrence of drug-drug interactions and adverse drug reactions,and take individualized medication treatment.
SARS-CoV-2renal transplantationrecipientdefined daily dose system
万方数据
维普
